Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Vera Therapeutics, Inc. Class A Common Stock

VERA

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Last trade $26.19
Day change -$0.78 (-2.89%)
Day range $25.83 – $30.53
Volume 768,875
Market cap $1.95B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.95B
Price / earnings
—
Price / book
5.85×
Price / sales
189.73×
EV / sales
191.69×
EV / EBITDA
-4.62×

Profitability

Earnings per share
-$5.76
Return on assets
-89.43%
Return on equity
-125.01%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.23×
Current ratio
7.91×
Quick ratio
7.78×
Cash ratio
0.99×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$376.05M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VERA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$10.28M$0$0$0$0$0$0$0
Cost of revenue$3.3M$0$0$0$0$0$0$0
Gross profit$6.98M$0$0$0$0$0$0$0
Selling, general and administrative$61.43M$52.41M$39.12M$34.9M$27.46M$21.95M$15.92M$15.57M
Research and development$41.25M$60.08M$86.01M$59.31M$56.47M$58.2M$41.28M$33.35M
Total operating expenses$102.68M$112.49M$125.13M$94.21M$83.93M$80.14M$57.19M$48.91M
Operating income-$95.7M-$112.49M-$125.13M-$94.21M-$83.93M-$80.14M-$57.19M-$48.91M
Interest expense-$1.87M-$1.85M-$1.82M-$1.9M-$1.96M-$1.87M-$1.79M-$1.87M
Income before taxes-$93.71M-$109.72M-$121.97M-$91.1M-$80.29M-$76.66M-$51.43M-$43.42M
Income taxes$0$0$0$1K$0$0$0$1K
Net income-$93.71M-$109.72M-$121.97M-$91.1M-$80.29M-$76.66M-$51.43M-$43.43M
Net income attributable to common shareholders-$93.71M-$109.72M-$121.97M-$91.1M-$80.29M-$76.66M-$51.43M-$43.43M
EBITDA-$94.88M-$112.36M-$124.99M-$94.07M-$83.8M-$80.02M-$57.11M-$48.86M
Basic earnings per share-$1.30-$1.52-$1.69-$1.39-$1.26-$1.20-$0.81-$0.72
Diluted earnings per share-$1.30-$1.52-$1.69-$1.39-$1.26-$1.20-$0.81-$0.72

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

Vera Therapeutics announced that William Turner, current Chief Regulatory Officer, will retire and transition to Strategic Advisor role in Q3 2026. Nancy Boman, M.D., Ph.D., with over 25 years of regulatory affairs experience, will succeed him. The transition follows the recent accelerated FDA approval of TRUTAKNA (atacicept-vymj), the company's first therapy for IgA nephropathy.

The Motley Fool

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics (VERA) during Q1 2026, valued at approximately $18.1 million. The position, which represented 2.0% of the fund's assets in the prior quarter, was fully exited. Despite the sale, Vera Therapeutics stock has surged 81.4% over the past year and outperformed the S&P 500 by 55 percentage points.

GlobeNewswire Inc.

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

GlobeNewswire Inc.

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and povetacicept to address the substantial unmet need for more effective and better-tolerated therapies.

The Motley Fool

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision

Deerfield Management Company increased its stake in Vera Therapeutics by 418,538 shares during Q4 2025, bringing its total position to $205.58 million (2.6% of fund AUM). Vera's stock has surged 50% over the past year as its lead drug candidate atacicept approaches an FDA decision on July 7, 2026, for treating IgA nephropathy. The company has sufficient cash reserves to fund operations through a potential approval and U.S. launch.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.